Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial
Journal
The lancet. HIV
Journal Volume
10
Journal Issue
10
Date Issued
2023-10
Author(s)
Avihingsanon, Anchalee
Lu, Hongzhou
Leong, Chee Loon
Koenig, Ellen
Kiertiburanakul, Sasisopin
Lee, Man-Po
Supparatpinyo, Khuanchai
Zhang, Fujie
Rahman, Sophia
D'Antoni, Michelle L
Wang, Hongyuan
Hindman, Jason T
Martin, Hal
Baeten, Jared M
Li, Taisheng
Abstract
For most adults with HIV-1 and hepatitis B virus (HBV) coinfection, initial recommended treatment is a tenofovir-containing antiretroviral regimen, but no randomised studies have compared tenofovir disoproxil fumarate with tenofovir alafenamide. We aimed to investigate whether bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for viral suppression in individuals with HIV-1 and HBV coinfection at 48 and 96 weeks.
SDGs
Type
journal article